Nurix
Chris Phelps has served as Senior Vice President and Head of Early Discovery at Nurix since January 2021. Chris has more than 10 years of experience in small molecule discovery, with a focus on DNA encoded library technology. Prior to joining Nurix, he served in multiple roles at GSK, most recently as Director of DNA Encoded Library Screening. He earned his bachelor’s degree in Biology from St. Lawrence University and his Ph.D. in Chemistry and Biochemistry from the University of California, San Diego, and completed his post-doctoral training at Harvard University.
Nurix
3 followers
Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. Nurix is focused on developing drugs to treat cancer including the novel, small molecule immuno-oncology agents.